Intervention thresholds for osteoporosis in the UK

Bone

Volumn 36, Issue 1, 2005, Pages 22-32

  Kanis, John A ^a   Borgstrom, Frederik ^b   Zethraeus, Niklas ^c   Johnell, Olof ^d   Oden, Anders ^e   Jönsson, Bengt ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b STOCKHOLM HEALTH ECONOMICS   (Sweden)

^c STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e NONE

Author keywords

Cost effectiveness; Hip fracture; Intervention threshold; Osteoporotic fracture

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; VITAMIN D;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; FRAGILITY FRACTURE; HEALTH CARE COST; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; MODEL; MORBIDITY; OSTEOPOROSIS; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SENSITIVITY ANALYSIS; TIME; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; DENSITOMETRY, X-RAY; GREAT BRITAIN; HIP FRACTURES; HUMANS; MIDDLE AGED; OSTEOPOROSIS; PROBABILITY; SENSITIVITY AND SPECIFICITY;

EID: 12344310388     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2004.08.018     Document Type: Article

References (79)

1. J.A. Kanis, C.-C. Gluer for the Committee of Scientific Advisors, International Osteoporosis Foundation An update on the diagnosis and assessment of osteoporosis with densitometry Osteoporos. Int. 11 2000 192 202
2. J.A. Kanis Diagnosis of osteoporosis and assessment of fracture risk Lancet 359 2002 1929 1936
3. Anonymous Statin therapy-What now? Drugs Ther. Bull. 39 2001 17 21
4. L.E. Ramsay, I.U. Haq, P.R. Jackson, and W.W. Yeo The Sheffield table for primary prevention of coronary heart disease. Corrected Lancet 348 1996 1251 1252
5. L.E. Ramsay, I.U. Haq, P.R. Jackson, W.W. Yeo, D.M. Pickin, and J.N. Payne Targeting lipid-lowering drug therapy for primary prevention of coronary artery disease: an updated Sheffield table Lancet 348 1996 387 388
6. D. Wood, G. DeBacker, O. Faergemon, I. Graham, G. Mancia, and K. Pyoralle Prevention of coronary heart disease in clinical practice: recommendations of the second joint task force of European and other societies on coronary prevention Atherosclerosis 140 1998 199 270
7. M. Johannesson At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention Eur. Heart J. 22 2001 919 925
8. J.A. Kanis, A. Oden, O. Johnell, B. Jonsson, C. De Laet, and A. Dawson The burden of osteoporotic fractures. A method for setting intervention thresholds Osteoporos. Int. 12 2001 417 427
9. J.A. Kanis, O. Johnell, A. Oden, F. Borgstrom, N. Zethraeus, and C. De Laet The risk and burden of vertebral fracture in Sweden Osteoporos. Int. 15 2004 20 26
10. National Osteoporosis Foundation Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effective analysis Osteoporos. Int. 8 Suppl. 4 1998 1 88
11. J.A. Kanis, O. Johnell, A. Oden, C. De Laet, A. Oglesby, and B. Jonsson Intervention thresholds for osteoporosis Bone 31 2002 26 31
12. J.A. Kanis, O. Johnell, A. Oden, F. Borgstrom, H. Johansson, and C. De Laet Intervention thresholds for osteoporosis in men and women. A study based on data from Sweden Osteoporos. Int. 2004 [in press]
13. J.A. Kanis, F. Borgstrom, O. Johnell, A. Oden, D. Sykes, and B. Jonsson Cost-effectiveness of raloxifene in the UK-an economic evaluation based on the MORE study Osteoporos. Int. 2004 [in press]
14. B. Jonsson, C. Christiansen, O. Johnell, and J. Hedbrandt Cost-effectiveness of fracture prevention in established osteoporosis Osteoporos. Int. 5 1995 136 142
15. B. Jonsson, C. Christiansen, O. Johnell, J. Hedbrandt, and G. Karlsson Cost-effectiveness of fracture prevention in established osteoporosis Scand. J. Rheumatol. 103 1996 30 40 [suppl]
16. B. Jonsson, J.A. Kanis, A. Dawson, A. Oden, and O. Johnell Effect and offset of effect of treatments for hip fracture on health outcomes Osteoporos. Int. 10 1999 193 199
17. O. Johnell, B. Jonsson, L. Jonsson, and D. Black Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures Pharmaco-Economics 21 2003 305 314
18. N. Zethraeus, M. Johannesson, and B. Jonsson A computer model to analyze the cost-effectiveness of hormone replacement therapy Int. J. Technol. Assess. Health Care 15 1999 352 365
19. J.A. Kanis, A. Dawson, A. Oden, O. Johnell, C. de Laet, and B. Jonsson Cost-effectiveness of preventing hip fracture in the general female population Osteoporos. Int. 12 2001 356 361
20. J.A. Kanis, F. Borgstrom, O. Johnell, and B. Jonsson Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women Osteoporos. Int. 2004 [in press]
21. N. Zethraeus, W. Ben Sedrine, F. Caulin, S. Corcaud, H.J. Gathon, and M. Haim Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis Osteoporos. Int. 13 2002 841 857
22. D.G. Seeley, W.S. Browner, M.C. Nevitt, H.K. Genant, J.C. Scott, S.R. Cummings for the Study of Osteoporotic Fractures Research Group Which fractures are associated with low appendicular bone mass in elderly women Ann. Intern. Med. 115 1991 837 842
23. B.R. Singer, G.J. McLauchlan, C.M. Robinson, and J. Christie Epidemiology of fractures in 15,000 adults. The influence of age and gender J. Bone Joint Surg. 80 1998 243 248
24. J.A. Kanis, O. Johnell, D.M. Black, R.W. Downs, S. Sarkar, and T. Fuerst Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of raloxifene evaluation trial Bone 33 2004 293 300
25. J. Kanis, J. Brazier, M. Stevenson, W. Calvert, and M.L. Jones Treatment of established osteoporosis: a systematic review and cost-utility analysis Health Technol. Assess. 6 2002 1 146
26. J.A. Kanis, O. Johnell, A. Oden, I. Sembo, I. Redlund-Johnell, and A. Dawson Long-term risk of osteoporotic fracture in Malmö Osteoporos. Int. 11 2000 669 674
27. A. Oden, A. Dawson, W. Dere, O. Johnell, B. Jonsson, and J.A. Kanis Lifetime risk of hip fracture is underestimated Osteoporos. Int. 8 1998 599 603
28. D. Marshall, O. Johnell, and H. Wedel Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures Br. Med. J. 312 1996 1254 1259
29. C.M. Klotzbuecher, P.D. Ross, P.B. Landsman, T.A. Abbott III, and M. Berger Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis J. Bone Miner. Res. 15 2000 721 739
30. J.A. Kanis, O. Johnell, A. Oden, B. Jonsson, A. Dawson, and W. Dere Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden Osteoporos. Int. 11 2000 120 127
31. J.A. Kanis, O. Johnell, C. De Laet, H. Johansson, A. Oden, and P. Delmas A meta-analysis of previous fracture and subsequent fracture risk Bone 35 2004 375 382
32. Technology Appraisals Series No 5. Guidance to manufacturers and sponsors. National Institute for Clinical Excellence; 2001
33. P. Dolan, and D.J. Torgerson The cost of treating osteoporotic fractures in the United Kingdom female population Osteoporos. Int. 8 1998 611 617
34. C.E. De Laet, B.A. van Hout, H. Burger, A.E. Weel, A. Hofman, and H.A. Pols Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study Osteoporos. Int. 10 1999 66 72
35. S.E. Gabriel, A.N.A. Tosteson, C.L. Leibson, C.S. Crowson, G.R. Pond, and C.S. Hammond Direct medical costs attributable to osteoporotic fractures Osteoporos. Int. 13 2002 323 330
36. L.J. Melton, S.E. Gabriel, C.S. Crowson, A.N.A. Tosteson, O. Johnell, and J.A. Kanis Cost equivalence of different osteoporotic fractures Osteoporos. Int. 14 2003 383 388
37. Interim Life Tables (2002) Government Actuary's Department.
38. J.A. Kanis, A. Oden, O. Johnell, C. De Laet, B. Jonsson, and A.K. Oglesby The components of excess mortality after hip fracture Bone 32 2003 468 473
39. M.J. Parker, and J.K. Anand What is the true mortality after hip fracture? Public Health 105 1991 443 446
40. C. Cooper, E.J. Atkinson, S.J. Jacobsen, W.M. O'Fallon, and L.J. Milton Population-based study of survival after osteoporotic fractures Am. J. Epidemiol. 137 1993 1001 1005
41. J.A. Cauley, D.E. Thompson, K.C. Ensrud, J.C. Scott, and D. Black Risk of mortality following clinical fractures Osteoporos. Int. 11 2000 556 561
42. J.R. Center, T.V. Nguyen, D. Schneider, P.N. Sambrook, and J.A. Eisman Mortality after all major types of osteoporotic fracture in men and women: an observational study Lancet 353 1999 878 882
43. T. Jalava, S. Sarna, L. Pylkkanen, B. Mawer, J.A. Kanis, and P. Selby Association between vertebral fracture and increased mortality in osteoporotic patients J. Bone Miner. Res. 18 2003 1254 1260
44. O. Johnell, J.A. Kanis, A. Odén, I. Sernbo, I. Redlund-Johnell, and C. Petterson Mortality after osteoporotic fractures Osteoporos. Int. 15 2004 38 42
45. J.A. Kanis, A. Oden, O. Johnell, C. De Laet, and B. Jonsson Excess mortality after hospitalisation for vertebral fracture Osteoporos. Int. 15 2004 108 112
46. Writing Group for the Women's Health Initiative Risks and benefits of estrogen plus proestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial JAMA 288 2002 321 333
47. M.C. Chapuy, M.E. Arlot, P.D. Delmas, and P.J. Meunier Effect of cholecalciferol treatment for 3 years on hip fractures in elderly women Br. Med. J. 308 1994 1081 1082
48. Netten A, Rees T, Harrison G. Unit cost of health and social care. Personal services research unit. University of Kent; 2001. www.ukc.ac.uk/PSSRU.
49. Zethraeus N, Borgstrom F, Johnell O, Kanis JA, Jonsson B. Costs and quality of life associated with osteoporosis related fractures-results of a Swedish Survey. Working paper series in Economics and Finance. Report 512, Stockholm School of Health Economics; 2002.
50. L. Lundberg Health-Related Quality of Life in Sweden, in Faculty of Pharmacy 1999 Uppsala University Uppsala
51. P. Kind, P. Dolan, C. Gudex, and A. Williams Variations in population health status: results from a United Kingdom national questionnaire survey BMJ 316 1998 736 741
52. J. Raftery NICE: faster access to modern treatments? Analysis of guidance on health technologies Br. Med. J. 323 2001 1300 1303
53. F. Borgstrom, O. Johnell, J.A. Kanis, A. Oden, D. Sykes, and B. Jonsson Cost-effectiveness of raloxifene. An economic evaluation based on Swedish data Pharmaco-Economics 2004 [in press]
54. L.J. Melton, C.S. Crowson, and W.M. O'Fallon Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time Osteoporos. Int. 9 1999 29 37
55. G. Jones, P.N. Nguyen, P.N. Sambroske, P.J. Kelly, C. Gilberg, and J.A. Eisman Symptomatic fracture incidence in elderly men and women. The Dubbo Osteoporosis Epidemiology Study (DOES) Osteoporos. Int. 4 1994 277 282
56. M. Johannesson, D. Meltzer, and R. O'Connor Incorporating future costs in medical cost-effectiveness analysis Med. Decis. Making 7 1997 382 389
57. D. Meltzer Accounting for future costs in medical cost-effectiveness analysis J. Health Econ. 16 1997 33 64
58. J.A. Kanis, and B. Jonsson Economic evaluation of interventions for osteoporosis Osteoporos. Int. 13 2002 765 767
59. D.M. Black, D. Thompson, S. Quandt, L. Palermo, K. Ensrud, and O. Johnell Alendronate reduces the risk of vertebral fracture in women with BMD T-scores above -2.5: results from the Fracture Intervention Trial (FIT) Osteoporos. Int. 13 Suppl. 1 2002 S27
60. R. Marens, O. Wang, J. Satterwhite, and B. Mitlak The skeletal response to teriparatide is largely independent of age, initial bone mineral density and prevalent vertebral fractures in postmenopausal women with osteoporosis J. Bone Miner. Res. 18 2003 18 23
61. S.R. Cummings, D.M. Black, D.E. Thompson, W.B. Applegate, E. Barret-Connor, and T.A. Musliner Effect of alendronate on risk for fractures in women with low BMD but without vertebral fractures JAMA 280 1998 2077 2082
62. M.R. McClung, P. Geusens, P.D. Miller, H. Zippel, W.G. Bensen, and C. Roux Effect of risedronate on the risk of hip fracture in elderly women. Hip intervention program study group N. Engl. J. Med. 344 2001 333 340
63. J.A. Kanis Diagnosis of osteoporosis and assessment of fracture risk Lancet 359 2002 1929 1936
64. C. De Laet, H. Johansson, O. Johnell, J.A. Kanis, E.V. McCloskey, and D. Mellstrom A meta-analysis of body mass index (BMI) as a predictor of fracture risk J. Bone Miner. Res. 18 Suppl. 2 2003 S21
65. O. Johnell, C. De Laet, H. Johansson, L.J. Melton, J. Eisman, and J. Reeve Oral corticosteroids increase fracture risk independently of BMD Osteoporos. Int. 13 Suppl. 1 2002 S14
66. P.D. Delmas, R. Eastell, P. Garnero, M.J. Seibel, J. Stepan for the Committee of Scientific Advisors of the International Osteoporosis Foundation The use of biochemical markers of bone turnover in osteoporosis Osteoporos. Int. 11 suppl. 6 2000 S2 S17
67. C. De Laet, A. Oden, O. Johnell, B. Jonsson, and J.A. Kanis The impact of the use of multiple risk factors for fracture on case finding strategies. A mathematical framework Osteoporos. Int. 2004 [in press]
68. R.M. Neer, C.D. Arnand, J.R. Zanchetta, R. Prince, G.A. Gaich, and J.Y. Reginster Effects of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N. Engl. J. Med. 344 2001 1434 1441
69. Y.Z. Bagger, L.B. Tanko, P. Alexanderson, H.B. Hansen, A. Mollgaard, and P. Raver Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study Bone 34 2004 728 735
70. D.M. Kado, W.S. Browner, L. Palermo, M.C. Nevitt, H.K. Genant, S.R. Cummings for the Study of Osteoporotic Fractures Research Group Vertebral fractures and mortality in older women Arch. Intern. Med. 159 1999 1215 1220
71. W.E. Bacon, S. Maggi, A. Looker, T. Harris, C.R. Nair, and J. Giaconi International comparison of hip fracture rates in 1988 to 1989 Osteoporos. Int. 6 1996 69 75
72. L. Elffors, E. Allander, J.A. Kanis, B. Gullberg, O. Johnell, and J. Dequeker The variable incidence of hip fracture in Southern Europe: the MEDOS Study Osteoporos. Int. 4 1994 253 263
73. O. Johnell, B. Gullberg, E. Allander, and J.A. Kanis The apparent incidence of hip fracture in Europe: a study of national register sources Osteoporos. Int. 2 1992 298 302
74. J.A. Kanis, O. Johnell, C. De Laet, B. Jonsson, A. Oden, and A. Oglesby International variations in hip fracture probabilities: implications for risk assessment J. Bone Miner. Res. 17 2002 1237 1244
75. Zethraeus N, Johannesson M, Jonsson B. A computer model to analyse the cost-effectiveness of hormone replacement therapy. EFI Research Paper No 6578, January. Stockholm School of Economics; 1998.
76. S.R. Cummings, S. Eckert, and K.A. Krueger The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial JAMA 281 1999 2189 2197
77. World Health Organisation. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843. WHO, Geneve; 1994.
78. B.E. Hillner, J.P. Hollenberg, and S.G. Pauker Postmenopausal estrogens in prevention of osteoporosis. Benefit virtually without risk if cardiovascular effect are considered Am. J. Med. 80 1986 1115 1127
79. Million Women Study Collaborators Breast cancer and hormone-replacement therapy in the million women study Lancet 362 2003 419 427